Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar tudósok krt 2, 1117, Budapest, Hungary.
Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000, Ljubljana, Slovenia.
J Comput Aided Mol Des. 2021 Feb;35(2):223-244. doi: 10.1007/s10822-020-00371-5. Epub 2021 Jan 18.
Here we present WIDOCK, a virtual screening protocol that supports the selection of diverse electrophiles as covalent inhibitors by incorporating ligand reactivity towards cysteine residues into AutoDock4. WIDOCK applies the reactive docking method (Backus et al. in Nature 534:570-574, 2016) and extends it into a virtual screening tool by introducing facile experimental or computational parametrization and a ligand focused evaluation scheme together with a retrospective and prospective validation against various therapeutically relevant targets. Parameters accounting for ligand reactivity are derived from experimental reaction kinetic data or alternatively from computed reaction barriers. The performance of this docking protocol was first evaluated by investigating compound series with diverse warhead chemotypes against KRAS, MurA and cathepsin B. In addition, WIDOCK was challenged on larger electrophilic libraries screened against OTUB2 and NUDT7. These retrospective analyses showed high sensitivity in retrieving experimental actives, by also leading to superior ROC curves, AUC values and better enrichments than the standard covalent docking tool available in AutoDock4 when compound collections with diverse warheads were investigated. Finally, we applied WIDOCK for the prospective identification of covalent human MAO-A inhibitors acting via a new mechanism by binding to Cys323. The inhibitory activity of several predicted compounds was experimentally confirmed and the labelling of Cys323 was proved by subsequent MS/MS measurements. These findings demonstrate the usefulness of WIDOCK as a warhead-sensitive, covalent virtual screening protocol.
在这里,我们提出了 WIDOCK,这是一种虚拟筛选协议,通过将配体对半胱氨酸残基的反应性纳入 AutoDock4 中,支持选择各种亲电试剂作为共价抑制剂。WIDOCK 应用反应性对接方法(Backus 等人在 Nature 534:570-574, 2016 中),并通过引入简便的实验或计算参数化以及配体为中心的评估方案,以及针对各种治疗相关靶标的回顾性和前瞻性验证,将其扩展为虚拟筛选工具。反映配体反应性的参数源自实验反应动力学数据或计算反应势垒。该对接协议的性能首先通过研究针对 KRAS、MurA 和组织蛋白酶 B 的具有不同弹头化学型的化合物系列进行评估。此外,还针对 OTUB2 和 NUDT7 筛选的更大亲电文库对 WIDOCK 进行了挑战。这些回顾性分析表明,通过对具有不同弹头的化合物库进行研究,WIDOCK 在检索实验活性方面具有很高的灵敏度,同时还导致 ROC 曲线、AUC 值和更好的富集度优于 AutoDock4 中可用的标准共价对接工具。最后,我们应用 WIDOCK 前瞻性地鉴定了通过与 Cys323 结合作用于新机制的共价人 MAO-A 抑制剂。通过实验证实了几种预测化合物的抑制活性,并通过随后的 MS/MS 测量证明了 Cys323 的标记。这些发现证明了 WIDOCK 作为一种弹头敏感的共价虚拟筛选协议的有用性。